Entasis Therapeutics Appoints David Meek as Chairman of the Board
June 24 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced that David Meek
has been appointed as Chairman of the Board of Directors, effective
immediately. Mr. Meek will succeed Nicholas Galakatos, Ph.D. who
will continue to serve as a director on the Board.
“The Board and I are thankful to Dr. Galakatos
for providing invaluable guidance to our leadership team as
Chairman of the Board over the past several years and we will
continue to benefit from his experience,” said Manos Perros,
President and Chief Executive Officer of Entasis. “Additionally, we
are very pleased to welcome David Meek as our new Chairman, as we
develop our late stage clinical candidates through pivotal trials
and prepare for commercialization. David brings extensive industry
experience to our Board and a strong commercial background in
oncology and rare diseases, providing a valuable strategic
perspective as we work to successfully develop and commercialize
our innovative pathogen-targeted treatments.”
Mr. Meek has over 25 years of experience in the
healthcare industry where he has held various global executive
positions at major pharmaceutical and biotechnology companies. He
is currently the Chief Executive Officer and Board member of Ipsen
Pharmaceuticals, a leading multinational pharmaceutical company
focused on developing innovative medicines in oncology,
neuroscience and rare diseases. He also serves on the Board of
Directors of uniQure, PhRMA, and EFPIA. Prior to joining Ipsen, Mr.
Meek was Executive Vice President and President of the oncology
division of Baxalta. Previously, he held executive positions at
Endocyte and Novartis. Mr. Meek began his career at Johnson &
Johnson and Janssen Pharmaceuticals. He holds a B.A. from the
University of Cincinnati.
“I look forward to working closely with the
Entasis board and management team and leveraging our collective
experiences to build on the strong foundation Nick has established
during his tenure as the Chairman of Entasis’ Board,” commented
David Meek. “Antimicrobial resistance is a global health issue and
Entasis is playing a lead role in developing new therapies. The
novel pathogen-targeted medicines in Entasis’ antimicrobial
pipeline represent a model-shift in the treatment of severe
multi-drug resistant infections and I am excited by the opportunity
to help translate our pipeline of programs to a portfolio of
successful, life-saving products.”
Dr. Galakatos added, “I am grateful to have had
the opportunity to serve as Chairman of the Entasis Board, and I am
pleased to transition this role to David. Entasis is a very
promising biopharmaceutical company and David is uniquely qualified
to provide strategic guidance as we progress our multiple
differentiated antimicrobial assets into the final stages of
clinical development and prepare for commercialization. I will
continue to work closely with the Board and the management team to
advance and support the Company's growth.”
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including ETX2514SUL
(targeting Acinetobacter baumannii infections),
zoliflodacin (targeting Neisseria gonorrhoeae), and
ETX0282CPDP (targeting Enterobacteriaceae infections).
Entasis is also using its platform to develop a novel class of
antibiotics, non-β-lactam inhibitors of the penicillin-binding
proteins (NBPs) (targeting Gram-negative infections). For more
information, visit www.entasistx.com.
Entasis Company Contact Kyle
Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations Contacts Tram Bui / Janhavi
Mohite The Ruth Group (646) 536-7035 / 7026 tbui@theruthgroup.com
jmohite@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024